Outcomes and toxicity of oral Fosfestrol in metastatic castration-resistant prostate cancer—a real-world experience

INTRODUCTION: Although there are multiple drugs approved for the treatment of metastatic castration-resistant prostate cancer (CRPC), the cost can be a limiting factor in using them in a resource-limited setting. Therefore, less expensive alternatives are the need of the hour. We have been using Fos...

Descripción completa

Detalles Bibliográficos
Autores principales: Nandini Devi, R, Praveen Kumar Shenoy, VP, Ismail, Irshad, Avaronnan, Manuprasad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Intelligence 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10550288/
https://www.ncbi.nlm.nih.gov/pubmed/37799959
http://dx.doi.org/10.3332/ecancer.2023.1589

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10550288/
https://www.ncbi.nlm.nih.gov/pubmed/37799959
http://dx.doi.org/10.3332/ecancer.2023.1589

Ejemplares similares